CO6910164A2 - Anticuerpos a pcsk9 y usos de los mismos - Google Patents

Anticuerpos a pcsk9 y usos de los mismos

Info

Publication number
CO6910164A2
CO6910164A2 CO14055604A CO14055604A CO6910164A2 CO 6910164 A2 CO6910164 A2 CO 6910164A2 CO 14055604 A CO14055604 A CO 14055604A CO 14055604 A CO14055604 A CO 14055604A CO 6910164 A2 CO6910164 A2 CO 6910164A2
Authority
CO
Colombia
Prior art keywords
pcsk9 antibodies
pcsk9
antibodies
Prior art date
Application number
CO14055604A
Other languages
English (en)
Inventor
Julian Davies
Barret Allan
Ryan James Darling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161535625P priority Critical
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6910164A2 publication Critical patent/CO6910164A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
CO14055604A 2011-09-16 2014-03-14 Anticuerpos a pcsk9 y usos de los mismos CO6910164A2 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201161535625P true 2011-09-16 2011-09-16

Publications (1)

Publication Number Publication Date
CO6910164A2 true CO6910164A2 (es) 2014-03-31

Family

ID=46881177

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14055604A CO6910164A2 (es) 2011-09-16 2014-03-14 Anticuerpos a pcsk9 y usos de los mismos

Country Status (28)

Country Link
US (1) US8530414B2 (es)
EP (1) EP2756003A1 (es)
JP (1) JP6013487B2 (es)
KR (1) KR101607783B1 (es)
CN (1) CN103781802B (es)
AP (1) AP201407499A0 (es)
AR (1) AR087715A1 (es)
AU (1) AU2012308786B2 (es)
BR (1) BR112014005799A2 (es)
CA (1) CA2845706C (es)
CL (1) CL2014000590A1 (es)
CO (1) CO6910164A2 (es)
CR (1) CR20140087A (es)
DO (1) DOP2014000041A (es)
EA (1) EA024430B1 (es)
EC (1) ECSP14013242A (es)
GT (1) GT201400049A (es)
IL (1) IL231282D0 (es)
MA (1) MA35433B1 (es)
MX (1) MX347475B (es)
NZ (1) NZ622393A (es)
PE (1) PE20141147A1 (es)
SG (1) SG2014014187A (es)
TN (1) TN2014000094A1 (es)
TW (1) TWI586687B (es)
UA (1) UA114604C2 (es)
WO (1) WO2013039958A1 (es)
ZA (1) ZA201401267B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311665A (zh) 2007-08-23 2015-01-28 安姆根有限公司 针对前蛋白转化酶枯草杆菌蛋白酶kexin 9型(pcsk9)的抗原结合蛋白
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
ME02760B (me) 2008-12-15 2018-01-20 Regeneron Pharma HIGH AFINITY ANTIBODY ANTIBODIES ACCORDING TO PCSK9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Proprotein convertase subtilisin / kexin 9 inhibitor (PCSK9) for use in reducing lipoprotein levels (a)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (en) 2013-06-07 2014-12-10 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP3004171A1 (en) 2013-06-07 2016-04-13 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
CA2916259A1 (en) * 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
EP2862877A1 (en) 2013-10-18 2015-04-22 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
WO2016008899A1 (en) 2014-07-15 2016-01-21 Kymab Limited Targeting human pcsk9 for cholesterol treatment
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
EP3332790A1 (en) 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
DE202015009007U1 (de) 2014-07-15 2016-08-19 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
CN105085684B (zh) * 2014-05-14 2020-04-17 上海亨臻实业有限公司 Pcsk9靶向重组疫苗设计及其应用
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
AU2015289613A1 (en) 2014-07-16 2017-02-02 Regeneron Pharmaceuticals, Inc. Methods for treating patients with heterozygous familial hypercholesterolemia (heFH)
CA2979756A1 (en) 2015-03-20 2016-09-29 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体
CN106810609A (zh) * 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用
US10793643B2 (en) 2015-12-31 2020-10-06 Jiangsu Hengrui Medicine Co., Ltd. PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof
JP2019509714A (ja) * 2016-01-05 2019-04-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. Pcsk9抗体、その抗原結合フラグメント及び医薬用途
US20200165354A1 (en) * 2016-09-20 2020-05-28 WuXi Biologics Ireland Limited Novel Anti-PCSK9 Antibodies
AU2017356219A1 (en) 2016-11-14 2019-05-30 Amgen Inc. Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease
JP2020512995A (ja) 2017-04-13 2020-04-30 カディラ ヘルスケア リミティド 新規ペプチドベースのpcsk9ワクチン

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001031007A2 (en) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
AU8047101A (en) 2000-08-11 2002-02-25 Lilly Co Eli Novel secreted proteins and their uses
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2083859A4 (en) 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonists of pcsk9
WO2008057459A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
US20100150937A1 (en) 2006-11-07 2010-06-17 Sparrow Carl P Antagonists of pcsk9
WO2008133647A2 (en) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
EP2137218A2 (en) 2007-04-13 2009-12-30 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
CN104311665A (zh) * 2007-08-23 2015-01-28 安姆根有限公司 针对前蛋白转化酶枯草杆菌蛋白酶kexin 9型(pcsk9)的抗原结合蛋白
NZ584902A (en) * 2007-10-26 2012-03-30 Schering Corp Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
CA2720681C (en) 2008-04-23 2016-08-02 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
ME02760B (me) * 2008-12-15 2018-01-20 Regeneron Pharma HIGH AFINITY ANTIBODY ANTIBODIES ACCORDING TO PCSK9
JP2013509191A (ja) * 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ax1およびax189pcsk9アンタゴニストおよびバリアント
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING

Also Published As

Publication number Publication date
NZ622393A (en) 2015-11-27
AU2012308786B2 (en) 2016-12-15
TN2014000094A1 (en) 2015-07-01
WO2013039958A1 (en) 2013-03-21
JP6013487B2 (ja) 2016-10-25
AU2012308786A1 (en) 2014-02-27
MA35433B1 (fr) 2014-09-01
CN103781802B (zh) 2016-08-24
UA114604C2 (uk) 2017-07-10
DOP2014000041A (es) 2014-06-30
CN103781802A (zh) 2014-05-07
KR101607783B1 (ko) 2016-03-30
ZA201401267B (en) 2015-11-25
SG2014014187A (en) 2014-05-29
GT201400049A (es) 2015-05-28
CR20140087A (es) 2014-05-02
PE20141147A1 (es) 2014-09-22
JP2014530188A (ja) 2014-11-17
CL2014000590A1 (es) 2014-10-17
IL231282D0 (en) 2014-04-30
US8530414B2 (en) 2013-09-10
EA201490470A1 (ru) 2014-06-30
BR112014005799A2 (pt) 2017-03-28
MX2014003175A (es) 2015-03-05
EP2756003A1 (en) 2014-07-23
AP201407499A0 (en) 2014-03-31
TW201323444A (zh) 2013-06-16
US20130071405A1 (en) 2013-03-21
MX347475B (es) 2017-04-27
CA2845706A1 (en) 2013-03-21
CA2845706C (en) 2016-03-22
EA024430B1 (ru) 2016-09-30
KR20140044939A (ko) 2014-04-15
AR087715A1 (es) 2014-04-09
TWI586687B (zh) 2017-06-11
ECSP14013242A (es) 2014-07-31

Similar Documents

Publication Publication Date Title
NO2019006I1 (no) Tisagenlekleucel
NO2019020I1 (no) lanadelumab
NO2019034I1 (no) lorlatinib
CL2015000027A1 (es) Anticuerpos e inmunoconjugados anti-cd22
NO2019038I1 (no) Risankizumab
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
CO6880063A2 (es) Hemifumarato de tenofovir alafenamida
CO7071115A2 (es) Asa
CO6930312A2 (es) Método de notificación de aplicación
CO6920260A2 (es) Ambiente de aplicación múltiple
CO6852047A2 (es) Wearable assembly
CO6801647A2 (es) Formulation for anti-α4β7 antibody
CO6852065A2 (es) Galleta saludable
CO6950440A2 (es) Pétidos cititóxicos y conjugados de anticuerpo-fármaco de los mismos
CO6862160A2 (es) Indazoles
CO6801776A2 (es) Cosmético
CL2016000251A1 (es) Anti-activin antibodies and uses thereof
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
CO6930343A2 (es) Conjunto conntenedor y método asociado
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
CO6862157A2 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimida y su uso como moduladores de receptoresde c5a
NO2018039I1 (no) Rukaparibkamsylat
CL2015000640A1 (es) Hppd variants and methods of use
CO7020865A2 (es) Microorganismos y métodos para producir alquenos
CO6940382A2 (es) Agentes de ligación a vegf/dll4 y usos de los mismos

Legal Events

Date Code Title Description
FG Application granted